However, many people experience a significant reduction in appetite within 1-4 weeks
Exenatide, the first GLP-1RA approved in 2005, demonstrated clinical efficacy but its low homology with human GLP-1 and gastrointestinal side effects restricted widespread use (Muttenthaler et al., 2021)
A vial that requires manual syringe drawing feels different from a pre-calibrated FlexTouch pen
They are not intended for human or animal consumption, diagnostic, therapeutic, or agricultural use
When used along with healthy eating, regular exercise, and a dedication to long-term changes, they can make a positive difference in a person's life
However, diabetic patients with concomitant sporadic medullary thyroid carcinomas that express GLP1R in 2030% should probably be excluded from any incretin treatment for their diabetes